117 related articles for article (PubMed ID: 21345814)
1. The efficacy of canakinumab in the treatment of a patient with familial Mediterranean fever and longstanding destructive arthritis.
Mitroulis I; Skendros P; Oikonomou A; Tzioufas AG; Ritis K
Ann Rheum Dis; 2011 Jul; 70(7):1347-8. PubMed ID: 21345814
[No Abstract] [Full Text] [Related]
2. Canakinumab induces remission in a patient with resistant familial Mediterranean fever.
Hacihamdioglu DO; Ozen S
Rheumatology (Oxford); 2012 Jun; 51(6):1041. PubMed ID: 22403182
[No Abstract] [Full Text] [Related]
3. Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.
De Benedetti F; Gattorno M; Anton J; Ben-Chetrit E; Frenkel J; Hoffman HM; Koné-Paut I; Lachmann HJ; Ozen S; Simon A; Zeft A; Calvo Penades I; Moutschen M; Quartier P; Kasapcopur O; Shcherbina A; Hofer M; Hashkes PJ; Van der Hilst J; Hara R; Bujan-Rivas S; Constantin T; Gul A; Livneh A; Brogan P; Cattalini M; Obici L; Lheritier K; Speziale A; Junge G
N Engl J Med; 2018 May; 378(20):1908-1919. PubMed ID: 29768139
[TBL] [Abstract][Full Text] [Related]
4. Infliximab therapy in a patient with familial Mediterranean fever and chronic hip arthritis.
Daysal S; Akcil G; Goker B; Haznedaroglu S; Ercan N; Ozturk MA
Arthritis Rheum; 2005 Feb; 53(1):146-7. PubMed ID: 15696552
[No Abstract] [Full Text] [Related]
5. Canakinumab in Children with Familial Mediterranean Fever: A Single-Center, Retrospective Analysis.
Kisla Ekinci RM; Balci S; Dogruel D; Altintas DU; Yilmaz M
Paediatr Drugs; 2019 Oct; 21(5):389-395. PubMed ID: 31463794
[TBL] [Abstract][Full Text] [Related]
6. Effect of interleukin-1 antagonists on the quality of life in familial Mediterranean fever patients.
Varan O; Kucuk H; Babaoglu H; Atas N; Salman RB; Satis H; Ozturk MA; Haznedaroglu S; Goker B; Tufan A
Clin Rheumatol; 2019 Apr; 38(4):1125-1130. PubMed ID: 30535829
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-1 targeting drugs in familial Mediterranean fever: a case series and a review of the literature.
Meinzer U; Quartier P; Alexandra JF; Hentgen V; Retornaz F; Koné-Paut I
Semin Arthritis Rheum; 2011 Oct; 41(2):265-71. PubMed ID: 21277619
[TBL] [Abstract][Full Text] [Related]
8. Canakinumab for the treatment of children with colchicine-resistant familial Mediterranean fever: a 6-month open-label, single-arm pilot study.
Brik R; Butbul-Aviel Y; Lubin S; Ben Dayan E; Rachmilewitz-Minei T; Tseng L; Hashkes PJ
Arthritis Rheumatol; 2014 Nov; 66(11):3241-3. PubMed ID: 25049046
[No Abstract] [Full Text] [Related]
9. Interleukin-1beta and the autoinflammatory diseases.
Dinarello CA
N Engl J Med; 2009 Jun; 360(23):2467-70. PubMed ID: 19494224
[No Abstract] [Full Text] [Related]
10. The medical odyssey of a boy with arthritis of familial Mediterranean fever.
Conca W; Ghatasheh G; Al-Salam S; Neidl Van Gorkom K
Int J Rheum Dis; 2012 Apr; 15(2):e37-9. PubMed ID: 22462434
[No Abstract] [Full Text] [Related]
11. Treatment of familial Mediterranean fever: colchicine and beyond.
Gül A
Isr Med Assoc J; 2014 May; 16(5):281-4. PubMed ID: 24979831
[No Abstract] [Full Text] [Related]
12. Effects of anti-tumor necrosis factor agents for familial mediterranean fever patients with chronic arthritis and/or sacroiliitis who were resistant to colchicine treatment.
Bilgen SA; Kilic L; Akdogan A; Kiraz S; Kalyoncu U; Karadag O; Ertenli I; Dogan I; Calguneri M
J Clin Rheumatol; 2011 Oct; 17(7):358-62. PubMed ID: 21946459
[TBL] [Abstract][Full Text] [Related]
13. IL-1beta-targeted antibody approved for rare autoinflammatory disorders.
Nat Rev Drug Discov; 2009 Aug; 8(8):605. PubMed ID: 19644468
[No Abstract] [Full Text] [Related]
14. Anakinra for the treatment of familial Mediterranean fever-associated spondyloarthritis.
Varan O; Kucuk H; Tufan A
Scand J Rheumatol; 2016; 45(3):252-3. PubMed ID: 26948937
[No Abstract] [Full Text] [Related]
15. Successful treatment with infliximab of a patient with tumor necrosis factor-associated periodic syndrome (TRAPS) who failed to respond to etanercept.
Krelenbaum M; Chaiton A
J Rheumatol; 2010 Aug; 37(8):1780-2. PubMed ID: 20675856
[No Abstract] [Full Text] [Related]
16. The efficacy of anakinra in an adolescent with colchicine-resistant familial Mediterranean fever.
Calligaris L; Marchetti F; Tommasini A; Ventura A
Eur J Pediatr; 2008 Jun; 167(6):695-6. PubMed ID: 17588171
[TBL] [Abstract][Full Text] [Related]
17. Anakinra suppresses familial Mediterranean fever crises in a colchicine-resistant patient.
Mitroulis I; Papadopoulos VP; Konstantinidis T; Ritis K
Neth J Med; 2008 Dec; 66(11):489-91. PubMed ID: 19075317
[TBL] [Abstract][Full Text] [Related]
18. The use of Canakinumab, a novel IL-1β long-acting inhibitor, in refractory adult-onset Still's disease.
Kontzias A; Efthimiou P
Semin Arthritis Rheum; 2012 Oct; 42(2):201-5. PubMed ID: 22512815
[TBL] [Abstract][Full Text] [Related]
19. [Anakinra in a case of fever familial Mediterranean].
Ferris Villanueva E; García Coronel M; Guerrero Bautista R
Farm Hosp; 2014 Sep; 38(5):446-8. PubMed ID: 25344140
[No Abstract] [Full Text] [Related]
20. Colchicine failure in familial Mediterranean fever and potential alternatives: embarking on the anakinra trial.
Ben-Zvi I; Livneh A
Isr Med Assoc J; 2014 May; 16(5):271-3. PubMed ID: 24979828
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
